IOL Chemicals and Pharmaceuticals Limited

rs,

C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Security Symbol: IOLCP Dear Sirs, Sub: Investor Presentation – Q1FY24 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-

35%

017 Largest producer of Ibuprofen and the only company worldwide being backward integrated with ~35% Global share Spread over a sprawling campus of over 150 acres Key Highlights Largest producer

30%

a Zero Discharge Effluent Treatment Plant 2nd Largest producer of Iso Butyl Benzene (IBB) with ~30% Global share Customer base across 80 countries Over 20 products are commercialized with 8 produc

14%

rom NMPA, China Q1FY24 Financial Performance 570.24 Revenues (Rs. cr) 79.92 EBITDA (Rs. cr) 14% EBITDA Margin 46.21 Profit After Tax (Rs. cr) 8% PAT Margin 5 Geographical and Segmental hig

8%

4 Revenues (Rs. cr) 79.92 EBITDA (Rs. cr) 14% EBITDA Margin 46.21 Profit After Tax (Rs. cr) 8% PAT Margin 5 Geographical and Segmental highlights Chemical Segment (Rs. crore) Pharma Segment

14.0%

sive Income Total Comprehensive Income Basic & Diluted EPS (INR) 563.2 7.1 570.3 490.4 79.9 14.0% 14.4 4.0 61.5 61.5 15.3 46.2 8.1% -1.2 45.0 7.9 565.0 5.2 570.2 509.0 61.2 10.7% 1

8.1%

asic & Diluted EPS (INR) 563.2 7.1 570.3 490.4 79.9 14.0% 14.4 4.0 61.5 61.5 15.3 46.2 8.1% -1.2 45.0 7.9 565.0 5.2 570.2 509.0 61.2 10.7% 11.0 3.4 46.8 46.8 11.9 34.9 6.2% -

10.7%

9 14.0% 14.4 4.0 61.5 61.5 15.3 46.2 8.1% -1.2 45.0 7.9 565.0 5.2 570.2 509.0 61.2 10.7% 11.0 3.4 46.8 46.8 11.9 34.9 6.2% -0.5 34.4 5.9 30.6% 330 bps 31.4% 32.4% 190bps 58

6.2%

2 8.1% -1.2 45.0 7.9 565.0 5.2 570.2 509.0 61.2 10.7% 11.0 3.4 46.8 46.8 11.9 34.9 6.2% -0.5 34.4 5.9 30.6% 330 bps 31.4% 32.4% 190bps 587.2 8.7 595.9 491.4 104.5 17.5% 12.

30.6%

9 565.0 5.2 570.2 509.0 61.2 10.7% 11.0 3.4 46.8 46.8 11.9 34.9 6.2% -0.5 34.4 5.9 30.6% 330 bps 31.4% 32.4% 190bps 587.2 8.7 595.9 491.4 104.5 17.5% 12.1 4.9 87.5 87.5 22.2

330 bps

0 5.2 570.2 509.0 61.2 10.7% 11.0 3.4 46.8 46.8 11.9 34.9 6.2% -0.5 34.4 5.9 30.6% 330 bps 31.4% 32.4% 190bps 587.2 8.7 595.9 491.4 104.5 17.5% 12.1 4.9 87.5 87.5 22.2 65.3 1

31.4%

70.2 509.0 61.2 10.7% 11.0 3.4 46.8 46.8 11.9 34.9 6.2% -0.5 34.4 5.9 30.6% 330 bps 31.4% 32.4% 190bps 587.2 8.7 595.9 491.4 104.5 17.5% 12.1 4.9 87.5 87.5 22.2 65.3 11.0% 0

Regulatory Filings

4

Investor Relations Advisors

1

Regulatory Filings

US/EU/ANVISA (Antidiabetic and potential antineoplastic used for patients with type 2 diabetes) Dedicated manufacturing block with an installed capacity of 7,2000 MT/Annum

Regulatory Filings

US/EU/ENVISA Paracetamol Lamotrigine Clopidogrel Bisulphate Metformin Hydrochloride Pantoprazole Sodium (Antiplatelet drug, used in cardiovascular therapies, preventing future heart attacks, strokes, and other clot-related diseases) Dedicated manufacturing facility with installed capacity of 240 MT/Annum, with a fully backward integrated process.

Regulatory Filings

US/EU/ENVISA/China ( Treatment for gastroesophageal reflux disease and promote healing of tissue damage caused by gastric acid) Fully backward integration process, commercialized with an installed capacity >200 MT/Annum

Regulatory Filings

US/EU/ENVISA 30 Summary Pharmaceutical Segment • Moving towards a well diversified product portfolio, that is a shift towards the non-ibuprofen business. • We have successfully implemented manufacturing processes for Pantoprazole, Clopidogrel, Levetiracetam, and other APIs. • Our creation of synergistic segments, such as combination products like Vildagliptin and Sitagliptin with Metformin and Losartan and Valsartan, further diversifies our portfolio and positions us for growth in specific therapeutic areas. Specialty Chemical Segment • Commenced plant for Acetic Anhydride with 25,000 TPA , which shall be used for captive • consumption as well as merchant sale Explored opportunities in diverse product categories such as plasticizers, amines, and diketene derivatives, enabling us to identify new products for future growth. 31 Thank You

Investor Relations Advisors

IOL Chemicals & Pharmaceuticals Ltd. Adfactorspr Pvt. Ltd. Mr. Pardeep Kumar Khanna, CFO pardeepkhanna@iolcp.com Darshan Mankad darshan.mankad@adfactorspr.com www.iolcp.com Hanishi Shah hanishi.shah@adfactorspr.com www.adfactorspr.com